UroGen Secures Patent Allowance for ZUSDURI, Extending Protection to 2044
URGN has more than doubled off its 52-week low of $13.79.
Summary
UroGen received a Notice of Allowance from the USPTO for a patent covering methods of treating recurrent LG-IR-NMIBC with ZUSDURI and UGN-103 without surgery. The patent, once issued, will expire in July 2044, significantly extending the IP runway for its lead commercial product and pipeline candidate. This follows positive 36-month durability data for ZUSDURI in May and the recent IND clearance for UGN-501. The allowance strengthens the exclusivity period for a drug already showing strong commercial uptake, with Q1 revenue up 109% quarter-over-quarter. It reduces near-term generic risk and supports the long-term revenue outlook.
At the time of this announcement, URGN was trading at $38.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $13.79 to $40.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.